

Technology Partners

Co-Diagnostics Genomic Testing



Co-Diagnostics, Inc. (Nasdaq: CODX), a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, patented, state-of-the-art diagnostics technology, approved by the FDA and the European Union (CE). The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The diagnostic tests can be conducted with a swab, saliva, or with blood.

Co-Diagnostics' Logix Smart COVID-19 Test uses the Company's CoPrimer technology to detect the presence of ribonucleic acid (RNA) of the novel strain of coronavirus in a real-time RT-PCR kit that targets conserved regions in the virus genome. The unique, proprietary structure of CoPrimers molecules creates reactions that are far more specific than competing PCR technologies, to better identify the presence of and distinguish between viruses, pathogens, cancer, or other attributes in agricultural or industrial applications. The prestigious Journal of Molecular Diagnostics deemed CoPrimers a TECHNICAL ADVANCE as they are 2.5 MILLION times more effective in reducing amplification errors.

CoPrimers' specificity also enables the identification of a broad spectrum of conditions in a single molecular diagnostic test procedure – known as Multiplexing – as opposed to conducting discrete individual procedures. Multiplexing enables a single test to identify numerous conditions, attributes, or genetic sequences simultaneously. Multiplexing has enormous implications on cost-efficiencies and time savings in molecular testing.

ADDITIONAL INFORMATION ABOUT CO-DIAGNOSTICS' PARTICIPATION IN 'KEYSTONE COVID RESPONSE AND MOST-FAVORED PRICING IS AVAILABLE ON REQUEST EXCLUSIVELY FROM THE GC3 STRATEGY OPERATIONS TEAM